Study wrapper · #347
Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
Editor's note
No abstract is available for this item, so this note is based on the title alone. It is a published commentary responding to Glen Spielmans's re-analysis of the Phase 3 bremelanotide (PT-141) trials — part of an ongoing scholarly exchange over how the RECONNECT data should be interpreted and whether the drug's benefit is clinically meaningful. The title signals a rebuttal ("Failure of a Meta-analysis"), suggesting it defends the original trial reporting against the re-analysis. Without the text, its specific arguments, evidence and conclusions cannot be assessed, and no findings can be attributed to it here. Readers tracking the bremelanotide efficacy debate should read this commentary together with the Spielmans re-analysis it answers and the original RECONNECT reports to see all sides. Treat the title's framing as a claim to be evaluated, not an established conclusion.
Plain-language abstract
No summary abstract is provided for this article, so this description relies only on its title, and its actual findings are unknown. The title indicates it is a commentary titled "Failure of a Meta-analysis," written in response to a re-analysis by Glen Spielmans of the Phase 3 trials of bremelanotide (PT-141) for low sexual desire in women. In other words, it is part of a back-and-forth debate in the scientific literature: one researcher re-examined the trial data and questioned the drug's benefit, and this piece appears to push back on that re-examination. Because the full text is not available here, we cannot say what specific points it makes, what evidence it presents, or what it concludes. Anyone following the disagreement over how well bremelanotide works would need to read this commentary alongside the re-analysis it responds to and the original trial publications.